1
|
Saur T, DeMarco SE, Ortiz A, Sliwoski GR, Hao L, Wang X, Cohen BM, Buttner EA. A genome-wide RNAi screen in Caenorhabditis elegans identifies the nicotinic acetylcholine receptor subunit ACR-7 as an antipsychotic drug target. PLoS Genet 2013; 9:e1003313. [PMID: 23468647 PMCID: PMC3585123 DOI: 10.1371/journal.pgen.1003313] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2012] [Accepted: 12/22/2012] [Indexed: 11/18/2022] Open
Abstract
We report a genome-wide RNA interference (RNAi) screen for Suppressors of Clozapine-induced Larval Arrest (scla genes) in Caenorhabditis elegans, the first genetic suppressor screen for antipsychotic drug (APD) targets in an animal. The screen identifies 40 suppressors, including the α-like nicotinic acetylcholine receptor (nAChR) homolog acr-7. We validate the requirement for acr-7 by showing that acr-7 knockout suppresses clozapine-induced larval arrest and that expression of a full-length translational GFP fusion construct rescues this phenotype. nAChR agonists phenocopy the developmental effects of clozapine, while nAChR antagonists partially block these effects. ACR-7 is strongly expressed in the pharynx, and clozapine inhibits pharyngeal pumping. acr-7 knockout and nAChR antagonists suppress clozapine-induced inhibition of pharyngeal pumping. These findings suggest that clozapine activates ACR-7 channels in pharyngeal muscle, leading to tetanus of pharyngeal muscle with consequent larval arrest. No APDs are known to activate nAChRs, but a number of studies indicate that α7-nAChR agonists may prove effective for the treatment of psychosis. α-like nAChR signaling is a mechanism through which clozapine may produce its therapeutic and/or toxic effects in humans, a hypothesis that could be tested following identification of the mammalian ortholog of C. elegans acr-7. Clozapine is the most effective medication for treatment-refractory schizophrenia but produces toxic side effects such as agranulocytosis, metabolic syndrome, and developmental defects after exposure early in life. However, clozapine's molecular mechanisms of action remain poorly understood. In past studies, we showed that pharmacogenomic experiments in C. elegans identify novel signaling pathways through which clozapine exerts its biological effects. Here, we report the first genetic suppressor screen for antipsychotic (APD) drug targets in an animal and identify 40 suppressors of clozapine-induced larval arrest, including the α-like nicotinic acetylcholine receptor (nAChR) acr-7. We validate our RNAi result by showing that an acr-7 knockout suppresses clozapine-induced larval arrest and inhibition of pharyngeal pumping. Expression of a full-length translational acr-7::GFP (Green Fluorescent Protein) construct in the acr-7 mutant rescues suppression of these phenotypes. Clozapine-induced phenotypes are phenocopied by nAChR agonists and blocked by nAChR antagonists. The results suggest that clozapine induces these phenotypes through activation of the ACR-7 receptor. Recent studies have underscored the potential importance of nAChRs in the pathophysiology of schizophrenia. A clearer understanding of APD mechanisms would facilitate the design of improved drugs and may inform our understanding, not only of drug mechanisms, but also of disease pathogenesis.
Collapse
Affiliation(s)
- Taixiang Saur
- Department of Psychiatry, Harvard Medical School, Boston, Massachusetts, United States of America
- Mailman Research Center, McLean Hospital, Belmont, Massachusetts, United States of America
| | - Sarah E. DeMarco
- Mailman Research Center, McLean Hospital, Belmont, Massachusetts, United States of America
| | - Angelica Ortiz
- Department of Molecular Pathology, University of Texas–MD Anderson Cancer Center, Houston, Texas, United States of America
| | - Gregory R. Sliwoski
- Department of Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America
| | - Limin Hao
- Department of Psychiatry, Harvard Medical School, Boston, Massachusetts, United States of America
- Mailman Research Center, McLean Hospital, Belmont, Massachusetts, United States of America
| | - Xin Wang
- Department of Psychiatry, Harvard Medical School, Boston, Massachusetts, United States of America
- Mailman Research Center, McLean Hospital, Belmont, Massachusetts, United States of America
| | - Bruce M. Cohen
- Department of Psychiatry, Harvard Medical School, Boston, Massachusetts, United States of America
- Mailman Research Center, McLean Hospital, Belmont, Massachusetts, United States of America
| | - Edgar A. Buttner
- Department of Psychiatry, Harvard Medical School, Boston, Massachusetts, United States of America
- Mailman Research Center, McLean Hospital, Belmont, Massachusetts, United States of America
- Department of Neurology, Harvard Medical School, Boston, Massachusetts, United States of America
- * E-mail:
| |
Collapse
|